Mixed Form of Hirsutism in an Adolescent Female and Laser Therapy

Besa Gacaferri Lumezi ^{1,*}; Aferdita Goci ²; Violeta Lokaj ¹; Hatixhe Latifi ¹; Natyra Karahoda ¹; Ganimete Minci ¹; Drita Telaku ³; Antigona Gercari ⁴; Allma Kocinaj ⁴

¹Department of Physiology and Immunology, University Clinical Center of Kosovo, Pristina, Kosovo

²Child and Adolescent Mental Health Center, University Clinical Center of Kosovo, Pristina, Kosovo

³Department of Pediatrics, University Clinical Center of Kosovo, Pristina, Kosovo

⁴Department of Dermatology, University Clinical Center of Kosovo, Pristina, Kosovo

*Corresponding Author: Besa Gacaferri Lumezi, Department of Physiology and Immunology, University Clinical Center of Kosovo, Bulevardi i deshmoreve p.n. 10 000, Prishtina, Kosovo. Tel/Fax: +37-744186036, E-mail: besa_gacaferri@yahoo.com

Received: December 1, 2012; Revised: June 5, 2013; Accepted: February 12, 2014

Introduction: Hirsutism is a common disorder of excess growth of terminal hair in an androgen-dependent male distribution in women, including the chin, upper lip, breasts, back, and abdomen. It is very important to identify the etiology of hirsutism and adequate treatment is prior to any cosmetic therapy.

Case Presentation: The case was a 17-year-old female with severe hirsutism, oligomenorrhea, and obesity. She was evaluated to identify the etiology and diagnosed as a case of polycystic ovarian syndrome (PCOS), nonclassic congenital adrenal hyperplasia (NC-CAH), and hyperandrogenic insulin-resistant acanthosis nigricans (HAIR-AN) syndrome, which is a rare combination of hirsutism etiology. She was successfully treated according to the underlying pathology, and laser photoepilation was used as the preferred hair removal method.

Discussion: Establishing the etiology, using the evidence-based strategies to improve hirsutism, and treating the underlying disorder, are essential for proper management of women with hirsutism.

Keywords: Hirsutism; PCOS; NC-CAH; Lasers

1. Introduction

Hirsutism is a common disorder of excess growth of terminal hair in women in areas characteristic for male distribution, such as chin, upper lip, breasts, back, and abdomen (1). Classically, hirsutism is considered a marker of increased androgen levels in females with increased production of androgens (i.e. testosterone), either by the adrenals or due to an ovarian disease. Ovarian types of hyperandrogenism are polycystic ovarian syndrome (PCOS) and ovarian tumors. Adrenal types include Cushing's syndrome, androgen-producing tumors, and congenital adrenal hyperplasia (CAH), most commonly due to 21-hydroxylase deficiency. Less common causes include the hyperandrogenic insulin-resistant acanthosis nigricans syndrome (HAIR-AN) (2).

PCOS affects 4%-12% of women of reproductive age. It is a conglomeration of symptoms with varied presentations such as hirsutism, acne, alopecia, anovulatory cycles, and obesity. According to ESHRE/ASRM consensus workshop at Rotterdam in 2003, diagnosis of PCOS is based on presence of any two of the following: 1) chronic anovulation, 2) clinical/biochemical parameters for hyperandrogenism, and 3) polycystic ovaries on ultrasonography (3). The disorder is commonly accompanied by insulin resistance

and infertility. Women often initiate medical care for a cluster of PCOS symptoms (infertility, hirsutism, and irregular menstrual cycles) that ultimately are not the most concerning medical consequences of PCOS (diabetes mellitus (DM), coronary artery disease (CAD), endometrial hyperplasia/cancer) (4). CAH due to steroid 21-hydroxylase (21OH) deficiency is one of the most common inborn endocrine disorders and is inherited as an autosomal recessive disease. Molecular abnormalities of the *CYP21A2* gene coding for the steroid 21OH enzyme, lead to various degrees of impaired cortisol and aldosterone synthesis and androgen excess (5). Mild late congenital adrenal hyperplasia is much more common than the classic form. Women with mild congenital hyperplasia often present hirsutism, oligomenorrhea, or infertility.

2. Case Presentation

A 17-year-old female referred with growth of terminal hair in androgen sensitive areas. Hirsutism was evaluated according to the Ferriman-Gallwey score. The total value was 34. She had severe hirsutism over sideburns, upper lip, and chin. She appeared very anxious and had low self-esteem with family history of hirsutism and diabetes.

Implication for health policy/practice/research/medical education:

This case report can help medical practitioners to treat patients with hirsutism.

Copyright © 2014, Iranian Red Crescent Medical Journal; Published by Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Table 1. Levels of Hormones in the Early Follicular Phase ^a

Hormones	Serum	Normal Range
FSH, IU/L	2.67	2.2-15
LH, IU/L	48.37	0.8-18
Prolactin, mIU/L	289.93	30-800
Estradiol, pmol/L	459.88	210-833
Progesterone, nmol/L	10.02	17-75
Cortisol-morning, nmol/L	670.23	260-720
Cortisol-evening, nmol/L	92.42	50-350
TSH, nIU/mL	6.07	0.3-5.0
T3, nmol/L	1.75	1.3-2.9
T4, nmol/L	100.99	58-166
Total testosterone, nmol/L	5.73	< 3
Free testosterone, pg/mL	5.02	0.45-3.17
Androstenedione, nmol/L	17.46	0.7-10.8
DHEAS, MmL/L	6.74	0.81-9.0
SHBG, nM	9.02	30-100
17-OH- progesterone, nmol/L	8.26	0.45-3.3
ACTH, pg/mL	105.97	< 40

^a Abbreviations: ACTH, adrenocorticotrophic hormone; DHEAS, dehydroepiandrosterone sulfate; FSH, follicle-stimulating hormone; LH, luteinizing hormone; SHBG, sex hormone-binding globulin.

Table 2. Oral Glucose Tolerance Test of Serum ^a

OGTT, h	0 min	30 min	60 min	120 min	180 min
Glucose, mmol/L	4.8	9.06	9.9	7.0	3.4
Insulin, μ IU/L	45.4	77.4	190.1	118.9	45.2
C-Peptide, ng/mL	7.45	10.62	16.20	11.2	7.8

^a Abbreviation: OGTT, oral glucose tolerance test.

Table 3. Normal Ranges of Oral Glucose Tolerance Test ^a

OGTT, h	0 min	30 min	60 min	120 min	180 min
Glucose, mmol/L	4.4-6.6	5.0-7.5	5.8-8.8	5.0-7.2	4.4-6.1
Insulin, μ IU/L	5.7-12	32-80	30-58	10.4-24.8	3.8-13.2
C-Peptide, ng/mL	1-2.1	3.5-10.2	6.3-12.1	7.2-11.8	1.0-3.4

^a Abbreviation: OGTT, oral glucose tolerance test.

mellitus. She did not have oily skin and acne. Menarha had started when she was 14 years old. Oligomenorrhea was present. She was not taking any medication. Hirsutism had appeared three years before she came for visit. Her weight was 98 kg, height 163 cm, and BMI 36.9 kg/m². She had central (android) obesity, and increased waist-to-hip ratio (> 0.80). Blood pressure was 160/100 mmHg. Acanthosis nigricans was present.

Laboratory investigation was performed with radioimmunoassay (RIA) and Immunoradiometric assay (IRMA) methods, in the Laboratory of Endocrinology, Department of Physiology and Immunology, University Clinical

Center of Kosovo, Prishtina, Kosovo, in January 2012. Blood was taken in the early follicular phase, (before 8:00 in the morning, and for the evening cortisol, at 16:00). Blood was taken for assessing the progesterone level in the middle of cycle (Table 1).

Oral glucose tolerance test (OGTT) was also performed. We measured the blood sugar before she drank liquid containing 75 g of glucose. We took blood to measure glucose, insulin and C-peptide every 30 and 60 minutes, for three hours (Tables 2 and 3).

Ultrasound tests of ovaries and abdomen did not show any changes, abnormal fluid, or mass. Magnetic resonance of head did not show any changes as well.

Figure 1. Before Therapy

Figure 2. During Therapy

Etiology of her hirsutism was CAH, PCOS without polycystic ovaries but with oligomenorrhea, clinical and biochemical hyperandrogenism, insulin resistance, hypertension, obesity, and acanthosis nigricans. Metformin and cyproterone acetate/ethinyl estradiol were prescribed for her. She was treated with long-pulse alexandrite laser, 755 nm. After medical therapy and four laser treatment sessions at six-week intervals, there were marked improvements in hirsutism. Her body weight

was reduced by 15 kg. Her follow up after six months showed improvements in hirsutism and regular menstrual cycle. She seemed very satisfied with the changes, her self-esteem was much higher, she reported feeling very happy (Figures 1 and 2)

3. Discussion

PCOS is a heterogeneous disorder, in which patients can present hyperandrogenism, menstrual irregularities including oligomenorrhea, amenorrhea and infertility, and dysmetabolic syndrome that includes impaired glucose tolerance, hyperlipidemia, and obesity (6). Hyperpigmentation or acanthosis nigricans may also be observed in 5% of obese women with insulin resistance. Ovary is usually source of excess androgen in women with PCOS. Hyperinsulinemia further exacerbates the problem by stimulating the thecal cells and reducing the sex hormone-binding globulin (SHBG). Insulin resistance can occur in up to 50% of patients with PCOS.

Increase in weight also results in reduction of SHBG, thereby increasing the free testosterone. Therefore, weight loss is an extremely important measure in treatment of hirsutism for women with PCOS. To be diagnosed with PCOS by Rotterdam criteria, a women must have two of the following three manifestations: irregular or absent ovulation, elevated levels of androgenic hormones, and/or enlarged ovaries containing at least 12 follicles each (7).

Of adolescent females, 25% have multifollicular ovaries, and polycystic-type ovaries can occur in up to 20%-30% of reproductive-age females and 10% of healthy, regularly menstruating ones, making the differentiation of "normal" versus "abnormal" ovaries difficult for even experienced specialists. Moreover, transvaginal or transabdominal ultrasound is often inappropriate for pediatric patients, particularly virginal girls (8). This was the reason of not performing transvaginal ultrasound for our patient.

Nonclassic congenital adrenal hyperplasia (NC-CAH) due to P450c21 (21-hydroxylase) deficiency is a common autosomal recessive disorder due to mutations in the CYP21A2 gene. NC-CAH can be present in childhood, adolescence, and adulthood. Symptoms include hirsutism, acne, alopecia, anovulation, and menstrual dysfunction. In a multicenter study, the most common symptoms among adolescent and adult women were hirsutism (59%), oligomenorrhea (54%), and acne (33%) (9). NC-CAH is diagnosed by confirming 17-hydroxyprogesterone and androstenedione (10).

Treatment of hirsutism should be undertaken using combination therapy, including androgen suppression, peripheral androgen blockade, mechanical/cosmetic amelioration, and destruction of the unwanted hairs. The most popular treatments for hirsutism are oral contraceptive (OC) medications, which suppress circulating luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to a decrease in ovarian androgen

production. They may also decrease adrenal androgen production by a mechanism not yet clear. The progestin in the birth control pill can lead to antagonism of 5 α -reductase and androgen receptor (11). Metformin treatment significantly improves insulin sensitivity in insulin-resistant patients (12). Hirsutism can cause a lot of psychological problems. Affected women may have anxiety and depression. In one study on hirsute women suffering from PCOS, the average time spent per week dealing with facial hair was 104 minutes and majority of women reported checking facial hair frequently in mirrors and by touch, and 75% showed clinically significant anxiety (13). Laser-assisted hair removal is a well-tolerated and effective technique for patients who desire permanent reduction of hair growth. The ideal patient for laser hair removal is light skin with black coarse hair. Establishing the etiology, using the evidence-based strategies to improve hirsutism, and treating the underlying disorder are essential for proper management of women with hirsutism.

Acknowledgements

There is no acknowledgment.

Author's Contribution

Besa Gacaferri Lumezi admitted the patient in the Endocrinology Laboratory, pointed out hirsutism according to Ferriman-Galwey score, and wrote the manuscript. Allma Kocinaj performed the laser treatment of the patient. Besa Gacaferri Lumezi, Hatixhe Latifi, Violeta Lokaj performed the lab tests. Aferdita Goci was the psychological counselor; Drita Telaku consulted the medical treatments. All authors read and approved the final manuscript. Natyra Karahoda, Hatixhe Latifi, Violeta Lokaj, Ganimete Minci, Aferdita Goci, Antigona Gercari were involved in drafting the manuscript and revising it critically for important intellectual content.

Financial Disclosure

The authors declared no competing interests.

Funding/Support

This study was self-funded.

References

1. Harrison S, Somani N, Bergfeld WF. Update on the management of hirsutism. *Cleve Clin J Med*. 2010;**77**(6):388-98.
2. Sachdeva S. Hirsutism: evaluation and treatment. *Indian J Dermatol*. 2010;**55**(1):3-7.
3. Saxena P, Prakash A, Nigam A, Mishra A. Polycystic ovary syndrome: Is obesity a sine qua non? A clinical, hormonal, and metabolic assessment in relation to body mass index. *Indian J Endocrinol Metab*. 2012;**16**(6):996-9.
4. Traub ML. Assessing and treating insulin resistance in women with polycystic ovarian syndrome. *World J Diabetes*. 2011;**2**(3):33-40.
5. Bidet M, Bellanne-Chantelot C, Galand-Portier MB, Golmard JL, Tardy V, Morel Y, et al. Fertility in women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. *J Clin Endocrinol Metab*. 2010;**95**(3):1182-90.
6. Somani N, Harrison S, Bergfeld WF. The clinical evaluation of hirsutism. *Dermatol Ther*. 2008;**21**(5):376-91.
7. Shah D, Patel S. Hirsutism. *Gynecol Endocrinol*. 2009;**25**(3):140-8.
8. Bremer AA. Polycystic ovary syndrome in the pediatric population. *Metab Syndr Relat Disord*. 2010;**8**(5):375-94.
9. Witchel SF, Azziz R. Nonclassic congenital adrenal hyperplasia. *Int J Pediatr Endocrinol*. 2010;**2010**:625105.
10. Singh RJ. Quantitation of 17-OH-progesterone (OHPG) for diagnosis of congenital adrenal hyperplasia (CAH). *Methods Mol Biol*. 2010;**603**:271-7.
11. Agrawal NK. Management of hirsutism. *Indian J Endocrinol Metab*. 2013;**17**(Suppl1):S77-82.
12. Nawrocka-Rutkowska J, Ciecwiez S, Marciniak A, Brodowska A, Wisniewska B, Kotlega D, et al. Insulin resistance assessment in patients with polycystic ovary syndrome using different diagnostic criteria-impact of metformin treatment. *Ann Agric Environ Med*. 2013;**20**(3):528-32.
13. Maziar A, Farsi N, Mandegarfar M, Babakoochi S, Gorouhi F, Dowlati Y, et al. Unwanted facial hair removal with laser treatment improves quality of life of patients. *J Cosmet Laser Ther*. 2010;**12**(1):7-9.